Navigation Links
Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Date:2/7/2008

PT. RICHMOND, Calif., Feb. 7 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. today announced that Glenn A. Oclassen, Chief Executive Officer & President, will present at the 10th Annual BIO CEO & Investor Conference at the Waldorf-Astoria Hotel in New York City on Tuesday, February 12, 2008 at 10:15 AM Eastern Time.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs. Transcept development projects leverage new understanding of CNS conditions to provide additional uses and enhanced clinical benefits for existing active agents. The lead Transcept product, Intermezzo(R) (zolpidem tartrate lozenge), is a low dose sublingual formulation of zolpidem for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep. Phase 3 clinical trials have been completed for Intermezzo(R) and Transcept plans to submit an NDA in the third quarter of 2008. Another product being developed by Transcept is TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for the treatment of dopamine associated psychiatric disorders. TO-2060 has recently completed a successful dose ranging trial for the treatment of alcohol use disorder and a full clinical development program has begun. For further information, please visit the company's website at: http://www.transcept.com.

Contacts:

Transcept Pharmaceuticals, Inc.

Michael Gill

Director of Communications

(510) 215-3575

mgill@transcept.com

The Ruth Group

Investors / Media

Stephanie Carrington / Jason Rando

(646) 536-7017 / 7025

scarrington@theruthgroup.com

jrando@theruthgroup
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
2. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
3. Transcept Pharmaceuticals to Present at 19th Annual Piper Jaffray Health Care Conference
4. Transcept Pharmaceuticals to Present at RBC Capital Markets 2007 Healthcare Conference
5. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... almost all types of cancer sends the protein factories ... a tumour,s uncontrolled growth, new research suggests. , Scientists ... molecular trigger responsible for ratcheting up activity of the ... the building blocks cancer cells need to keep growing. ... SREBP, controls the flow of messages to the endoplasmic ...
(Date:7/9/2014)... type of lung cancer, researchers have uncovered mutations in ... tumors. The new knowledge may expand treatments for patients ... are available or are in clinical trials. , Reporting ... Cancer Genome Atlas (TCGA), including researchers at Washington University ... and other institutions, studied tumors from 230 patients with ...
(Date:7/9/2014)... a relatively optimistic picture of women,s chances of surviving ... the chest wall or skin, but not beyond. ... size and whether they have involved lymph nodes, are ... advanced" tumors, suggesting that they are a relatively serious ... breast cancers of this and other types account for ...
(Date:7/9/2014)... BostonPractices used in policing injection drug users in ... mortality. , A study, conducted by researchers ... Health, in collaboration with St. Petersburg Pavlov State ... had on the health outcomes of a cohort ... use. , Those who were arrested by police ...
(Date:7/9/2014)... feelings are personal and subjective, the human brain ... represents emotions across different senses, situations and even ... neuroscientist Adam Anderson. , "We discovered that fine-grained ... an area of the brain associated with emotional ... an individual,s subjective feeling," says Anderson, associate professor ...
Breaking Medicine News(10 mins):Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Lung cancer study hints at new treatments 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Study cracks how the brain processes emotions 2
... (HealthDay News) -- Men with high amounts of the controversial ... have impaired semen quality, a new study of factory workers ... National Institute of Occupational Safety and Health, found high urine ... drop in sperm concentration, overall sperm count, sperm vitality and ...
... Wisconsin are conducting the KAST clinical trial at ... of a new vertebral augmentation treatment (Kiva) for ... Sean Tutton, M.D, associate professor ... is principal interventional radiology investigator for this multi-institutional, ...
... Reporter , THURSDAY, Oct. 28 (HealthDay News) -- Better treatments are ... AIDS-causing virus takes a toll that will challenge the health care ... HIV-positive men and women ages 50 and older living in New ... much higher rate than others their age without HIV. And ...
... in everything from laws about using your cell phone while ... pass on fourth down come to Austin on November 7, ... people who use math for a living but also problem ... of the Institute for Operations Research and the Management Sciences ...
... to different prescription drug plans because Part D reimbursements ... the actual costs incurred, according to a study released ... describes how a system designed to encourage competition and ... led companies to raise their premiums in an effort ...
... HealthDay Reporter , THURSDAY, Oct. 28 (HealthDay News) -- ... might help protect women from breast cancer, a new, ... "We found no overall association between green tea intake ... who have habitually drunk green tea," said lead researcher ...
Cached Medicine News:Health News:Plastics Chemical BPA Tied to Poor Sperm Quality 2Health News:Plastics Chemical BPA Tied to Poor Sperm Quality 3Health News:National research study to assess new treatment for painful vertebral fractures 2Health News:More Older Americans Living With HIV 2Health News:More Older Americans Living With HIV 3Health News:4,000 numbers crunchers count on Austin 2Health News:Study identifies flaws in Medicare prescription drug program 2Health News:Study Finds Green Tea Offers No Protection From Breast Cancer 2
(Date:1/15/2014)...  In an unprecedented effort to curb the spread of "superbugs" such ... vehicles, an advanced and portable UV germicidal lamp manufactured by MRSA-UV ... In order to prevent EMS paramedics and transport ... West Palm Beach Fire Rescue is the first in ...
(Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ... CGM System as a non-invasive, wireless continuous glucose monitoring ... Executive Chairman and Interim CEO of Echo Therapeutics, will ... Equity Conference. Mr. Doman will make ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... , NEW YORK, Nov. 17 ... research report is available in its catalogue. ... Biomaterials 2009 (15 Countries) , ... 2008, the combined European biomaterial market was ...
... , BEIJING, ... developer and provider of vaccines in China, announced today that ... Administration,for Panflu.1, the Company,s H1N1 vaccine. The population has been ... for PANFLU.1 was extended to,one year from six months. , ...
Cached Medicine Technology:Reportlinker Adds European Markets for Orthopedic Biomaterials 2009 (15 Countries) 2Sinovac's PANFLU.1 (H1N1) Regulatory Approval Expanded to Include Geriatric Population 2
Sabre 180, 230V, 50Hz is a powerful niche generator....
High performance capabilities in a multipurpose generator, blended cut modes, simultaneous independent coagulation, low voltage coagulation, valleylab REM safety substantially reduces the risk of pat...
Lorgnette pinhole occluder...
Black multi-pinhole occluder...
Medicine Products: